AXL Is a Novel Predictive Factor and Therapeutic Target for Radioactive Iodine Refractory Thyroid Cancer
出版年份 2019 全文链接
标题
AXL Is a Novel Predictive Factor and Therapeutic Target for Radioactive Iodine Refractory Thyroid Cancer
作者
关键词
-
出版物
Cancers
Volume 11, Issue 6, Pages 785
出版商
MDPI AG
发表日期
2019-06-07
DOI
10.3390/cancers11060785
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- The role of TERT promoter mutations in postoperative and preoperative diagnosis and prognosis in thyroid cancer
- (2018) Anqi Jin et al. MEDICINE
- Epigenetic Modifications in Thyroid Cancer Cells Restore NIS and Radio-Iodine Uptake and Promote Cell Death
- (2018) Sabine Wächter et al. Journal of Clinical Medicine
- Targeting oncogenic Raf protein-serine/threonine kinases in human cancers
- (2018) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Information for Clinicians: Approach to the Patient with Progressive Radioiodine-Refractory Thyroid Cancer—When to Use Systemic Therapy
- (2017) Maria E. Cabanillas et al. THYROID
- American Thyroid Association Guidelines on the Management of Thyroid Nodules and Differentiated Thyroid Cancer Task Force Review and Recommendation on the Proposed Renaming of Encapsulated Follicular Variant Papillary Thyroid Carcinoma Without Invasion to Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features
- (2017) Bryan R. Haugen et al. THYROID
- RelA/p65 inhibition prevents tendon adhesion by modulating inflammation, cell proliferation and apoptosis
- (2017) Shuai Chen et al. Cell Death & Disease
- Molecular insights of Gas6/TAM in cancer development and therapy
- (2017) Guiling Wu et al. Cell Death & Disease
- Multiple anti-tumor effects of Reparixin on thyroid cancer
- (2017) Federica Liotti et al. Oncotarget
- Formyl peptide receptor 1 suppresses gastric cancer angiogenesis and growth by exploiting inflammation resolution pathways
- (2017) Nella Prevete et al. OncoImmunology
- Integrated analysis of gene expression and copy number identified potential cancer driver genes with amplification-dependent overexpression in 1,454 solid tumors
- (2017) Keiichi Ohshima et al. Scientific Reports
- 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: What is new and what has changed?
- (2016) Bryan R. Haugen CANCER
- Signal Transducer and Activator of Transcription 1 Plays a Pivotal Role in RET/PTC3 Oncogene-induced Expression of Indoleamine 2,3-Dioxygenase 1
- (2016) Sonia Moretti et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Sustained ERK inhibition maximizes responses of BrafV600E thyroid cancers to radioiodine
- (2016) James Nagarajah et al. JOURNAL OF CLINICAL INVESTIGATION
- Biologic and Clinical Perspectives on Thyroid Cancer
- (2016) James A. Fagin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Interleukin-8, but Not the Related Chemokine CXCL1, Sustains an Autocrine Circuit Necessary for the Properties and Functions of Thyroid Cancer Stem Cells
- (2016) Federica Liotti et al. STEM CELLS
- Adipose microenvironment promotes triple negative breast cancer cell invasiveness and dissemination by producing CCL5
- (2016) Vittoria D'Esposito et al. Oncotarget
- Enhancement of human sodium iodide symporter gene therapy for breast cancer by HDAC inhibitor mediated transcriptional modulation
- (2016) Madhura G. Kelkar et al. Scientific Reports
- AXL is an oncotarget in human colorectal cancer
- (2015) Erika Martinelli et al. Oncotarget
- Integrated Genomic Characterization of Papillary Thyroid Carcinoma
- (2014) Nishant Agrawal et al. CELL
- Molecular Mechanism of 17-Allylamino-17-demethoxygeldanamycin (17-AAG)-induced AXL Receptor Tyrosine Kinase Degradation
- (2013) Gnana Prakasam Krishnamoorthy et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Different expression of TSH receptor and NIS genes in thyroid cancer: role of epigenetics
- (2013) Maria D'Agostino et al. JOURNAL OF MOLECULAR ENDOCRINOLOGY
- Progress in molecular-based management of differentiated thyroid cancer
- (2013) Mingzhao Xing et al. LANCET
- Selumetinib-Enhanced Radioiodine Uptake in Advanced Thyroid Cancer
- (2013) Alan L. Ho et al. NEW ENGLAND JOURNAL OF MEDICINE
- Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
- (2013) J. Gao et al. Science Signaling
- Axl is essential for VEGF-A-dependent activation of PI3K/Akt
- (2012) Guo-Xiang Ruan et al. EMBO JOURNAL
- The receptor tyrosine kinase Axl is an essential regulator of prostate cancer proliferation and tumor growth and represents a new therapeutic target
- (2012) J D Paccez et al. ONCOGENE
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.
- (2012) Ethan Cerami et al. Cancer Discovery
- Activation of TYRO3/AXL Tyrosine Kinase Receptors in Thyroid Cancer
- (2011) E. Avilla et al. CANCER RESEARCH
- Papillary thyroid carcinoma: an update
- (2011) Virginia A LiVolsi MODERN PATHOLOGY
- Molecular genetics and diagnosis of thyroid cancer
- (2011) Yuri E. Nikiforov et al. Nature Reviews Endocrinology
- Regulation of Axl receptor tyrosine kinase expression by miR-34a and miR-199a/b in solid cancer
- (2011) G Mudduluru et al. ONCOGENE
- Induction, regulation, and biologic function of Axl receptor tyrosine kinase in Kaposi sarcoma
- (2010) R. Liu et al. BLOOD
- A novel mechanism of sodium iodide symporter repression in differentiated thyroid cancer
- (2009) V. E. Smith et al. JOURNAL OF CELL SCIENCE
- The cancer genome
- (2009) Michael R. Stratton et al. NATURE
- The human receptor tyrosine kinase Axl gene - promoter characterization and regulation of constitutive expression by Sp1, Sp3, and CpG methylation
- (2008) Giridhar Mudduluru et al. BIOSCIENCE REPORTS
- Phosphoinositide-3-kinase inhibition induces sodium/iodide symporter expression in rat thyroid cells and human papillary thyroid cancer cells
- (2008) Takahiko Kogai et al. JOURNAL OF ENDOCRINOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More